These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 35217606)
1. Nanobodies as allosteric modulators of Parkinson's disease-associated LRRK2. Singh RK; Soliman A; Guaitoli G; Störmer E; von Zweydorf F; Dal Maso T; Oun A; Van Rillaer L; Schmidt SH; Chatterjee D; David JA; Pardon E; Schwartz TU; Knapp S; Kennedy EJ; Steyaert J; Herberg FW; Kortholt A; Gloeckner CJ; Versées W Proc Natl Acad Sci U S A; 2022 Mar; 119(9):. PubMed ID: 35217606 [TBL] [Abstract][Full Text] [Related]
2. Allosteric modulation of the GTPase activity of a bacterial LRRK2 homolog by conformation-specific Nanobodies. Leemans M; Galicia C; Deyaert E; Daems E; Krause L; Paesmans J; Pardon E; Steyaert J; Kortholt A; Sobott F; Klostermeier D; Versées W Biochem J; 2020 Apr; 477(7):1203-1218. PubMed ID: 32167135 [TBL] [Abstract][Full Text] [Related]
3. The Parkinson's disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human. Mir R; Tonelli F; Lis P; Macartney T; Polinski NK; Martinez TN; Chou MY; Howden AJM; König T; Hotzy C; Milenkovic I; Brücke T; Zimprich A; Sammler E; Alessi DR Biochem J; 2018 Jun; 475(11):1861-1883. PubMed ID: 29743203 [TBL] [Abstract][Full Text] [Related]
4. Allosteric inhibition of LRRK2, where are we now. Soliman A; Cankara FN; Kortholt A Biochem Soc Trans; 2020 Oct; 48(5):2185-2194. PubMed ID: 33079169 [TBL] [Abstract][Full Text] [Related]
5. A designed ankyrin-repeat protein that targets Parkinson's disease-associated LRRK2. Dederer V; Sanz Murillo M; Karasmanis EP; Hatch KS; Chatterjee D; Preuss F; Abdul Azeez KR; Nguyen LV; Galicia C; Dreier B; Plückthun A; Versees W; Mathea S; Leschziner AE; Reck-Peterson SL; Knapp S J Biol Chem; 2024 Jul; 300(7):107469. PubMed ID: 38876305 [TBL] [Abstract][Full Text] [Related]
6. Dysregulated phosphorylation of Rab GTPases by LRRK2 induces neurodegeneration. Jeong GR; Jang EH; Bae JR; Jun S; Kang HC; Park CH; Shin JH; Yamamoto Y; Tanaka-Yamamoto K; Dawson VL; Dawson TM; Hur EM; Lee BD Mol Neurodegener; 2018 Feb; 13(1):8. PubMed ID: 29439717 [TBL] [Abstract][Full Text] [Related]
7. LRRK2 and Rab GTPases. Pfeffer SR Biochem Soc Trans; 2018 Dec; 46(6):1707-1712. PubMed ID: 30467121 [TBL] [Abstract][Full Text] [Related]
8. Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases. Steger M; Tonelli F; Ito G; Davies P; Trost M; Vetter M; Wachter S; Lorentzen E; Duddy G; Wilson S; Baptista MA; Fiske BK; Fell MJ; Morrow JA; Reith AD; Alessi DR; Mann M Elife; 2016 Jan; 5():. PubMed ID: 26824392 [TBL] [Abstract][Full Text] [Related]
9. Endogenous Rab38 regulates LRRK2's membrane recruitment and substrate Rab phosphorylation in melanocytes. Unapanta A; Shavarebi F; Porath J; Shen Y; Balen C; Nguyen A; Tseng J; Leong WS; Liu M; Lis P; Di Pietro SM; Hiniker A J Biol Chem; 2023 Oct; 299(10):105192. PubMed ID: 37625589 [TBL] [Abstract][Full Text] [Related]
10. The Roc domain of LRRK2 as a hub for protein-protein interactions: a focus on PAK6 and its impact on RAB phosphorylation. Cogo S; Ho FY; Tosoni E; Tomkins JE; Tessari I; Iannotta L; Montine TJ; Manzoni C; Lewis PA; Bubacco L; Chartier Harlin MC; Taymans JM; Kortholt A; Nichols J; Cendron L; Civiero L; Greggio E Brain Res; 2022 Mar; 1778():147781. PubMed ID: 35016853 [TBL] [Abstract][Full Text] [Related]
11. Vitamin B Schaffner A; Li X; Gomez-Llorente Y; Leandrou E; Memou A; Clemente N; Yao C; Afsari F; Zhi L; Pan N; Morohashi K; Hua X; Zhou MM; Wang C; Zhang H; Chen SG; Elliott CJ; Rideout H; Ubarretxena-Belandia I; Yue Z Cell Res; 2019 Apr; 29(4):313-329. PubMed ID: 30858560 [TBL] [Abstract][Full Text] [Related]
12. Development of phospho-specific Rab protein antibodies to monitor Lis P; Burel S; Steger M; Mann M; Brown F; Diez F; Tonelli F; Holton JL; Ho PW; Ho SL; Chou MY; Polinski NK; Martinez TN; Davies P; Alessi DR Biochem J; 2018 Jan; 475(1):1-22. PubMed ID: 29127256 [TBL] [Abstract][Full Text] [Related]
13. Parkinson's disease-associated mutant LRRK2 phosphorylates Rab7L1 and modifies trans-Golgi morphology. Fujimoto T; Kuwahara T; Eguchi T; Sakurai M; Komori T; Iwatsubo T Biochem Biophys Res Commun; 2018 Jan; 495(2):1708-1715. PubMed ID: 29223392 [TBL] [Abstract][Full Text] [Related]
18. Structural insights into the GTP-driven monomerization and activation of a bacterial LRRK2 homolog using allosteric nanobodies. Galicia C; Guaitoli G; Fislage M; Gloeckner CJ; Versées W Elife; 2024 Apr; 13():. PubMed ID: 38666771 [TBL] [Abstract][Full Text] [Related]
19. Leucine-rich repeat kinase 2 and Parkinson's disease. Kang UB; Marto JA Proteomics; 2017 Jan; 17(1-2):. PubMed ID: 27723254 [TBL] [Abstract][Full Text] [Related]
20. Allosteric Inhibition of Parkinson's-Linked LRRK2 by Constrained Peptides. Helton LG; Soliman A; von Zweydorf F; Kentros M; Manschwetus JT; Hall S; Gilsbach B; Ho FY; Athanasopoulos PS; Singh RK; LeClair TJ; Versées W; Raimondi F; Herberg FW; Gloeckner CJ; Rideout H; Kortholt A; Kennedy EJ ACS Chem Biol; 2021 Nov; 16(11):2326-2338. PubMed ID: 34496561 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]